The ERC1 Knockout Raji Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population derived from the Raji B lymphoblastoid cell line, exhibiting targeted disruption of the ERC1 gene. This polyclonal knockout model is designed to facilitate loss-of-function studies of ELKS/ERC1, a scaffolding protein critical for assembling the I??B kinase (IKK) complex and promoting NF-??B signaling. The use of a polyclonal format provides a heterogeneous population of knockout alleles, enabling robust functional analyses while mitigating clonal artifacts often associated with single-cell-derived lines. These cells are suited for investigating ERC1-dependent signaling pathways, including NF-??B activation and intracellular membrane trafficking, in a relevant B-cell lymphoma context.
The Raji cell line is an Epstein-Barr virus (EBV)-positive Burkitt lymphoma-derived B lymphoblastoid model that grows in suspension and harbors the characteristic t(8;14) chromosomal translocation, which juxtaposes the c-Myc oncogene with the immunoglobulin heavy-chain locus, driving constitutive c-Myc expression. This cell line exhibits constitutive NF-??B activation due to EBV-encoded latent membrane proteins and viral oncogenes, simulating a state of persistent pro-survival signaling that is central to EBV-driven lymphomagenesis. As a widely used model for aggressive B-cell lymphoma, Raji cells provide an appropriate platform for dissecting the molecular mechanisms governing lymphoma cell proliferation and survival, particularly in the context of NF-??B pathway dysregulation.
ERC1 (also known as ELKS) is a scaffolding protein that nucleates the assembly of the IKK complex??comprising IKK??, IKK??, and NEMO??thereby mediating signal-dependent activation of the NF-??B transcription factor family. In B lymphocytes, ERC1 responds to diverse upstream stimuli, including TNF-??, CD40 ligand, B-cell receptor engagement, and IL-1??, to promote phosphorylation and degradation of I??B??, liberating NF-??B p65/p50 dimers for nuclear translocation and transcription of target genes such as IL-6, c-Myc, and Bcl-xL. Beyond NF-??B signaling, ERC1 interacts with Rab6 to regulate intracellular vesicle transport, and associates with synaptic components like CAST and RIM1 in neuronal contexts, though in lymphocytes its trafficking role may influence cytokine secretion and surface receptor presentation.
In the Raji background, ERC1 knockout disrupts a central node in the constitutively active NF-??B circuit, potentially reducing the expression of pro-survival and proliferative genes and altering the trafficking of signaling molecules or secretory pathways. The EBV-driven phenotype of Raji cells amplifies the relevance of this model for studying how ERC1-mediated scaffolding integrates viral oncogenic signals with host pathways. Because Raji cells exhibit high baseline NF-??B activity, the loss of ERC1 provides a clean tool for assessing the contribution of ERC1-dependent complex assembly to the overall NF-??B output and downstream cellular phenotypes, including resistance to apoptosis and uncontrolled growth. This model is thus particularly informative for dissecting scaffolding functions in an environment where IKK complex formation is limiting or dysregulated.
Researchers can employ ERC1 Knockout Raji Polyclonal Cells to investigate the dynamics of NF-??B signaling in B-cell lymphoma through techniques such as NF-??B luciferase reporter assays, Western blotting for phospho-I??B?? and total I??B??, flow cytometric detection of NF-??B nuclear translocation, and quantitative PCR analysis of NF-??B target genes. The model is suitable for functional screening of small-molecule inhibitors targeting the IKK complex or upstream regulators, and for synthetic lethality screens that exploit the genetic vulnerability introduced by ERC1 loss. Additionally, these cells facilitate studies on vesicular trafficking in hematopoietic cells, including cytokine secretion assays (e.g., IL-6 ELISA) and analysis of surface receptor recycling, and can be integrated with proliferation (CellTiter-Glo) and apoptosis (Annexin V) assays to evaluate ERC1-dependent survival mechanisms. For detailed product specifications or technical inquiries, contact Ascent Research.
